Skip to main content

REVIEW article

Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1525380
This article is part of the Research Topic How Underappreciated Autoinflammatory Mechanisms (Innate Immunity) Dominate Disparate Autoimmune Disorders View all 3 articles

Recent Advances in the Role of Mesenchymal Stem Cells as Modulators in Autoinflammatory Diseases

Provisionally accepted
Baiyu Chen Baiyu Chen Zhilei Chen Zhilei Chen Mengfei He Mengfei He Lijie Zhang Lijie Zhang Longyan Yang Longyan Yang Lingling Wei Lingling Wei *
  • Beijing Key Laboratory of Diabetes Research and Prevention, Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China

The final, formatted version of the article will be published soon.

    Mesenchymal stem cells (MSCs), recognized for their self-renewal and multilineage differentiation capabilities, have garnered considerable wide attention since their discovery in bone marrow. Recent studies have underscored the potential of MSCs in immune regulation, particularly in the context of autoimmune diseases, which arise from immune system imbalances and necessitate long-term treatment. Traditional immunosuppressive drugs, while effective, can lead to drug tolerance and adverse effects, including a heightened risk of infections and malignancies. Consequently, adjuvant therapy incorporating MSCs has emerged as a promising new treatment strategy, leveraging their immunomodulatory properties. This paper reviews the immunomodulatory mechanisms of MSCs and their application in autoimmune diseases, highlighting their potential to regulate immune responses and reduce inflammation. The immunomodulatory mechanisms of MSCs are primarily mediated through direct cell contact and paracrine activity with immune cells. This review lays the groundwork for the broader clinical application of MSCs in the future and underscores their significant scientific value and application prospects. Further research is expected to enhance the efficacy and safety of MSCs based treatments for autoimmune diseases.

    Keywords: Mesenchymal Stem Cells, Immunomodulation, Autoimmune Diseases, Cell to cell contact, paracrine signaling, cell therapy

    Received: 09 Nov 2024; Accepted: 02 Dec 2024.

    Copyright: © 2024 Chen, Chen, He, Zhang, Yang and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Lingling Wei, Beijing Key Laboratory of Diabetes Research and Prevention, Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.